The University of Chicago Header Logo

Connection

Mark J. Ratain to Drug Approval

This is a "connection" page, showing publications Mark J. Ratain has written about Drug Approval.
Connection Strength

2.438
  1. Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs? JAMA Oncol. 2023 Nov 01; 9(11):1489-1490.
    View in: PubMed
    Score: 0.908
  2. Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab. Clin Pharmacol Ther. 2021 07; 110(1):29-31.
    View in: PubMed
    Score: 0.738
  3. Oncology micro-cap stocks: caveat emptor! J Natl Cancer Inst. 2011 Oct 19; 103(20):1488-9.
    View in: PubMed
    Score: 0.392
  4. Phase II oncology trials: let's be positive. Clin Cancer Res. 2005 Aug 15; 11(16):5661-2.
    View in: PubMed
    Score: 0.257
  5. Targeted therapies: redefining the primary objective of phase I oncology trials. Nat Rev Clin Oncol. 2014 Sep; 11(9):503-4.
    View in: PubMed
    Score: 0.120
  6. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.